BR112015012548A2 - método - Google Patents

método

Info

Publication number
BR112015012548A2
BR112015012548A2 BR112015012548A BR112015012548A BR112015012548A2 BR 112015012548 A2 BR112015012548 A2 BR 112015012548A2 BR 112015012548 A BR112015012548 A BR 112015012548A BR 112015012548 A BR112015012548 A BR 112015012548A BR 112015012548 A2 BR112015012548 A2 BR 112015012548A2
Authority
BR
Brazil
Prior art keywords
patient
expression level
gene expression
level information
breast cancer
Prior art date
Application number
BR112015012548A
Other languages
English (en)
Inventor
Janevski Angel
Harris Lyndsay
Dimitrova Nevenka
Banerjee Nilanjana
Kamalakaran Sitharthan
Varadan Vinay
Original Assignee
Koninklijke Philips Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koninklijke Philips Nv filed Critical Koninklijke Philips Nv
Publication of BR112015012548A2 publication Critical patent/BR112015012548A2/pt

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/30—Prediction of properties of chemical compounds, compositions or mixtures
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Data Mining & Analysis (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioethics (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Software Systems (AREA)
  • Evolutionary Computation (AREA)
  • Databases & Information Systems (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Artificial Intelligence (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

resumo método em um teste de avaliação de resultado de previsão para prever se uma paciente que é submetida a um regime de tratamento de câncer de mama irá alcançar uma resposta patológica completa (pcr), as informações de nível de expressão de gene diferencial são geradas para um conjunto de genes de entrada que pertencem à trajetória de sinalização de tgf-?. as informações de nível de expressão de gene diferencial comparam as informações de nível de expressão de gene de linha de base a partir de uma amostra de linha de base (70) de um tumor de mama de uma paciente adquiridas antes do início (71) de um regime de terapia de câncer de mama aplicado à paciente e as informações de nível de expressão de gene de resposta a partir de uma amostra de resposta (72) do tumor de mama adquiridas após o início do regime de terapia de câncer de mama mediante a administração de uma primeira dose de bevacizumab aplicada à paciente. uma previsão de pcr para a paciente é calculada com base nas informações de nível de expressão de gene diferencial do conjunto de genes de entrada que pertence à trajetória de sinalização de tgf-?. são revelados também métodos de desenvolvimento de teste de avaliação de resultado de previsão relacionados. 1/1
BR112015012548A 2012-12-03 2013-11-22 método BR112015012548A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261732472P 2012-12-03 2012-12-03
PCT/IB2013/060326 WO2014087294A2 (en) 2012-12-03 2013-11-22 Predictive outcome assessment for chemotherapy with neoadjuvant bevacizumab

Publications (1)

Publication Number Publication Date
BR112015012548A2 true BR112015012548A2 (pt) 2017-07-11

Family

ID=50030352

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015012548A BR112015012548A2 (pt) 2012-12-03 2013-11-22 método

Country Status (5)

Country Link
US (1) US10460831B2 (pt)
EP (1) EP2925887B1 (pt)
JP (1) JP6445451B2 (pt)
BR (1) BR112015012548A2 (pt)
WO (1) WO2014087294A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016062891A1 (en) * 2014-10-24 2016-04-28 Koninklijke Philips N.V. ASSESSMENT OF TGF-β CELLULAR SIGNALING PATHWAY ACTIVITY USING MATHEMATICAL MODELLING OF TARGET GENE EXPRESSION
CA2996513A1 (en) * 2015-08-25 2018-03-02 President And Fellows Of Harvard College Methods and compositions relating to the diagnosis and treatment of cancer
JP6922444B2 (ja) * 2016-11-11 2021-08-18 コニカミノルタ株式会社 蛍光ナノ粒子を用いた、病理学的完全奏効（ｐＣＲ）の予測を支援するための検査支援方法
US10902591B2 (en) * 2018-02-09 2021-01-26 Case Western Reserve University Predicting pathological complete response to neoadjuvant chemotherapy from baseline breast dynamic contrast enhanced magnetic resonance imaging (DCE-MRI)
CN110923318B (zh) * 2019-12-10 2022-02-11 中国医学科学院肿瘤医院 用于在乳腺癌患者中预测新辅助化疗疗效的标志物及其应用
WO2021156137A1 (en) 2020-02-04 2021-08-12 Oslo Universitetssykehus Hf Biomarkers predicting clinical response of a vegf-a inhibitory drug in cancer patients, method for their selection and use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007507222A (ja) 2003-05-28 2007-03-29 ゲノミック ヘルス， インコーポレイテッド 化学療法に対する応答を予測するための遺伝子発現マーカー
KR20150097813A (ko) 2006-12-19 2015-08-26 제넨테크, 인크. 조기 종양의 치료 및 아주반트 및 네오아주반트 요법을 위한 ｖｅｇｆ－특이적 길항제
BR112012003077A2 (pt) * 2009-08-14 2019-09-24 Genentech Inc mercadorias biologicas para monitorar resposta em paciente para antagonistas de vegf
WO2011153224A2 (en) * 2010-06-02 2011-12-08 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
MX2012013874A (es) 2010-06-03 2013-01-24 Abraxis Bioscience Llc Uso de la signatura en el microentorno de sparc en el tratamiento de cancer.
EP2670866A4 (en) 2011-04-05 2015-09-02 Translational Genomics Res Inst BIOMARKERS AND METHODS OF USE

Also Published As

Publication number Publication date
EP2925887B1 (en) 2018-03-07
WO2014087294A2 (en) 2014-06-12
JP2016508710A (ja) 2016-03-24
US10460831B2 (en) 2019-10-29
WO2014087294A3 (en) 2014-10-16
EP2925887A2 (en) 2015-10-07
US20150347679A1 (en) 2015-12-03
JP6445451B2 (ja) 2018-12-26

Similar Documents

Publication Publication Date Title
BR112015012548A2 (pt) método
Saâda-Bouzid et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
MX2023002251A (es) Antagonistas de union al eje pd-l1 y usos de los mismos para el tratamiento de cancer.
MX2017014736A (es) Metodos terapeuticos y diagnosticos para cancer.
BR112015004229A2 (pt) ensaios de diagnósticos e kits para a deteção de receptor 1 do folato
BR112015023120A2 (pt) método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
BR112016002000A2 (pt) Diagnóstico e terapia de câncer envolvendo células-tronco tumorais
BR112015015131A2 (pt) método, aparelho, mídia de armazenamento não transitório, programa de computador, e produto
BR112012020101A2 (pt) método diagnósticos e terapêuticos usando anticorpos anti-cd200.
BR112016007864A2 (pt) método para a prognose e tratamento de metástase de câncer
BR112015007144A2 (pt) uso de masitinib para o tratamento de câncer em subpopulações de paciente identificadas usando fatores prognosticadores
Pietrantonio et al. A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer
BR112014024219A8 (pt) Métodos de determinação, de otimização da eficácia terapêutica, de monitoramento, de seleção de terapia e de diagnóstico de distúrbio e kit
WO2018183817A3 (en) Tumor burden as measured by cell free dna
PH12014502410A1 (en) Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression
BR112016016635A2 (pt) Método e aparelho para isolar células invasivas e metastáticas para avaliação terapêutica e previsão de capacidade metastática
BR112012026224A2 (pt) métodos para tratar mal de alzheimer e para avaliar a eficácia de uma terapia
Au et al. Expression of ankyrin repeat and SOCS box containing 4 (ASB4) confers migration and invasion properties of hepatocellular carcinoma cells
BR112015031950A2 (pt) métodos para tratamento de câncer de ovário
Zhang et al. HCG18 participates in vascular invasion of hepatocellular carcinoma by regulating macrophages and tumor stem cells
MX2021003214A (es) Metodos terapeuticos y de diagnostico para el cancer de vejiga.
Koshy et al. The Effect of Radiotherapy Dose on Survival in Stage III Non–Small-Cell Lung Cancer Patients Undergoing Definitive Chemoradiotherapy
WO2013188823A3 (en) Cancer prognostic assays
AR089833A1 (es) Biomarcador predictivo para el tratamiento del cancer con anticuerpos de adcc incrementada
BR112015022621A2 (pt) métodos para detecção e tratamento de mieloma múltiplo

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements